Answers are grounded in this paper and cite their sources.
BACKGROUND: Treatment that reduces systemic corticosteroid (SCS)-related adverse effects but maintains disease control is of broad public health importance. OBJECTIVE: To evaluate the effect of mepolizumab vs long-term SCS use on SCS-related adverse effects in patients with severe asthma. METHODS: This retrospective, longitudinal cohort study (GSK Identification: US 218950) used claims data from the Optum Clinformatics Data Mart database from November 2014 to December 2022. Eligible patients (aged ≥12 years with ≥2 asthma diagnostic claims), had at least 2 mepolizumab claims (mepolizumab-treated cohort) or at least 6 months of continuous SCS use (long-term SCS-treated cohort). Inverse probability of treatment weighting was used to balance cohort characteristics. The primary outcome was SCS-related adverse effects. The secondary outcomes included exacerbation frequency, SCS/oral corticosteroid use, healthcare resource utilization, and costs (excluding the cost of therapy). RESULTS: Overall, 1219 (mepolizumab-treated) and 835 (long-term SCS-treated) patients with severe asthma were included (median follow-up, 12 months). Cohorts were well-balanced after weighting (mean age, 63-65 years; 66% female). The mepolizumab-treated cohort had significant reductions in overall, acute, and long-term SCS-related adverse effects (rate ratio [CI] 0.80 [0.70-0.92], 0.63 [0.47-0.84], and 0.80 [0.70-0.92], respectively) vs the long-term SCS-treated cohort; SCS dose reduction of 4.7 mg/d corresponds to a 20% reduction in SCS-related adverse effects (P = .002). Similar trends were observed in exacerbation rates, healthcare resource utilization, and medical costs, although not all reached statistical significance. CONCLUSION: Mepolizumab treatment reduced acute and long-term corticosteroid effects in patients with severe asthma vs long-term SCS use, suggesting avoidance of corticosteroid use can lead to measurable regression of SCS-associated adverse effects and more favorable disease trajectory.
No takes yet. Share an insight, caveat, or question.
Lugogo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: